Cite
LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.
MLA
Mok, T. S. K., et al. “LBA8 Nivolumab (NIVO) + Chemotherapy (Chemo) vs Chemo in Patients (Pts) with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (MNSCLC) with Disease Progression after EGFR Tyrosine Kinase Inhibitors (TKIs) in CheckMate 722.” Annals of Oncology, vol. 33, Nov. 2022, pp. S1561–62. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.10.350.
APA
Mok, T. S. K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y.-L., Gainor, J., Lee, S.-H., Chiu, C.-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M.-C., Samol, J., Zhang, X., Sylvester, J., Li, S., & Yang, J. .-H. (2022). LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Annals of Oncology, 33, S1561–S1562. https://doi.org/10.1016/j.annonc.2022.10.350
Chicago
Mok, T.S.K., K. Nakagawa, K. Park, Y. Ohe, N. Girard, H.R. Kim, Y-L. Wu, et al. 2022. “LBA8 Nivolumab (NIVO) + Chemotherapy (Chemo) vs Chemo in Patients (Pts) with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (MNSCLC) with Disease Progression after EGFR Tyrosine Kinase Inhibitors (TKIs) in CheckMate 722.” Annals of Oncology 33 (November): S1561–62. doi:10.1016/j.annonc.2022.10.350.